Its ability to specifically deliver secondary reagents, including chemotherapeutics [29], therapeutic anti-miRNA [26–28] and even antibodies [22, 23] to EGFR-positive cancer cells and tumors has been extensively demonstrated by our and other groups. The gene discussed is EGFR; the disease is cancer.